BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Sees Large Growth in Short Interest

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 111,892 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 360,667 shares, the short-interest ratio is currently 0.3 days. Currently, 0.4% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th.

Insider Buying and Selling at BlossomHill Therapeutics

In related news, Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the director owned 3,614,034 shares of the company’s stock, valued at approximately $57,824,544. This trade represents a 9.47% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 1,573,900 shares of company stock valued at $25,181,900 in the last ninety days.

BlossomHill Therapeutics Price Performance

Shares of NASDAQ BLSM opened at $18.30 on Tuesday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $20.61.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.